ScreenerHero

SABSSAB Biotherapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · sab.bio
3.780USD0.00%Mkt Cap: 343.93M $P/E: 15.75

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap343.93M $
Enterprise Value239.15M $
Revenue (TTM)—
Gross Profit-48.27M $
Net Income (TTM)13.27M $
Revenue/Share—
Last Price3.780 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees86
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)15.75
P/E (Forward)-3.88
PEG—
EV/EBITDA-3.48
EV/Revenue—
P/S—
P/B1.44
EPS (TTM)0.23
EPS (Forward)-0.95
52W Range
1.85058% of range5.150
52W High5.150 USD
52W Low1.850 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE8.76%
ROA7.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-44.78M $
CapEx (TTM)933.16K $
FCF Margin—
FCF Yield-8.39%
Net Debt-97.50M $
Net Debt/EBITDA1.42
Balance Sheet
Debt/Equity0.04
Current Ratio9.22
Quick Ratio8.93
Book Value/Sh2.572 USD
Cash/Share1.128 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJan 5, 2024
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)11.64 USD
Upside (mean)+207.8%
Target Range6.000 USD – 16.00 USD
$6.000+207.8% to mean$16.00
# Analysts11
Ownership
Shares Out.90.99M
Float62.04M
Insiders0.71%
Institutions75.42%
Short Interest
Short Ratio9.4d
Short % Float5.78%
Short % Out.5.58%
Shares Short4.66M
Short (prev mo.)3.77M
Technical
SMA 503.724 (+1.5%)
SMA 2003.792 (-0.3%)
Beta0.53
S&P 52W Chg18.16%
Avg Vol (30d)449.24K
Avg Vol (10d)335.59K
Technical Indicators
RSI (14)53.6
MACD0.0274
MACD Signal0.0207
MACD Hist.+0.0067
BB Upper3.985 USD
BB Middle3.693 USD
BB Lower3.402 USD
BB Width15.77%
ATR (14)0.1625 USD
Vol Ratio (20d)0.43x